NIH Studies in New England Journal of Medicine Favor Chromosomal Microarray Analysis Over Standard Karyotyping for Genetic

NIH Studies in New England Journal of Medicine Favor Chromosomal Microarray
Analysis Over Standard Karyotyping for Genetic Analysis

Largest Head-to-Head Studies Comparing the Two Diagnostic Tools; CombiMatrix:
Only Publicly-Traded Diagnostic Laboratory Specializing in Microarray Analysis

IRVINE, Calif., Dec. 7, 2012 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company performing DNA-based testing
services for developmental disorders and cancer diagnostics, today announced
that a pair of studies published in a leading journal favor chromosomal
microarray analysis (CMA) over traditional karyotyping for genetic prenatal
diagnosis and genetic evaluation of stillbirths. The two large studies,
published in the current edition of the New England Journal of Medicine,
represent the largest head-to-head studies comparing CMA to traditional
karyotyping. Both concluded that CMA identified additional, clinically
significant genetic abnormalities compared to karyotyping in both the prenatal
diagnostic setting as well as the evaluation of stillbirths.

Ronald Wapner, M.D., one of the nation's leading clinicians in the field of
reproductive genetics and the lead author of the prenatal diagnosis study and
a co-author on the stillbirth study, has called for CMA to replace
karyotyping, which has been the traditional standard of care for these tests.
Wapner is the Director of Reproductive Genetics at New York Presbyterian
Hospital/Columbia University Medical Center, and the Vice Chairman of Research
and Professor of Obstetrics and Gynecology at Columbia College of Physicians
and Surgeons.

While Wapner noted that the transition to CMA from karyotyping in clinical
practice will be gradual, as physicians and patients continue to be educated
about its use, the two studies make the choice clear: "Why would anyone want
to continue to use the standard method, which gives only part of the answer?"
Dr. Wapner said in a statement published earlier this year by the New York
Presbyterian and Columbia University Medical Center.

The larger of the two studies, entitled "Chromosomal Microarray Versus
Karyotyping for Prenatal Diagnosis," enrolled 4,406 women. In 4,340 (98.8
percent) of the fetal samples, microarray analysis was successful. The second
study, entitled "Karyotype Versus Microarray Testing for Genetic Abnormalities
After Stillbirth," 532 stillbirths were analyzed. That study concluded that
"microarray analysis is more likely than karyotype analysis to provide a
genetic diagnosis, primarily because of its success with nonviable tissue, and
is especially valuable in analyses of stillbirths with congenital anomalies…"

Both studies were funded by the Eunice Kennedy Shriver National Institute of
Child Health and Human Development—part of the National Institutes of Health
(NIH).

R. Judd Jessup, President and CEO of CombiMatrix, the only publicly-traded
company that specializes in CMA, noted that the studies showed conclusively
the value of microarray testing. "The CMA test could eventually give parents,
physicians and educators better tools for anticipatory care by proactively
addressing the impacts of many chromosomal disorders," Jessup said.

In the case of stillbirths or miscarriages, especially when it happens more
than once, "CMA can be used to determine if there is a genetic reason for
these occurrences, and can give parents valuable information about future
pregnancies," says Jessup.

About CombiMatrix Corporation

CombiMatrix Corporation, through its wholly owned subsidiary, CombiMatrix
Molecular Diagnostics, Inc. (CMDX), is a molecular diagnostics laboratory
which offers DNA-based testing services to the prenatal, pediatric and
oncology markets. The Company performs genetic testing utilizing Microarray,
FISH, PCR and G-Band Chromosome Analysis.CMDX offers prenatal and pediatric
testing services for the detection of abnormalities of genes at the DNA level
beyond what can be identified through traditional technologies.CMDX was also
the first commercial clinical laboratory in the United States to make
comprehensive DNA-based genomic analysis of solid tumors, including breast,
colon, lung, prostate and brain tumors, available to oncology patients and
medical professionals.Additional information about CMDX is available at
www.cmdiagnostics.com or by calling 1-800-710-0624.

Safe Harbor Statement under the Private Securities Litigation Reform Act of
1995

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995.These statements are based upon our current expectations, speak only
as of the date hereof and are subject to change.All statements, other than
statements of historical fact included in this press release, are
forward-looking statements.Forward-looking statements can often be identified
by words such as "anticipates," "expects," "intends," "plans," "goal,"
"predicts," "believes," "seeks," "estimates," "may," "will," "should,"
"would," "could," "potential," "continue," "ongoing," "objective," similar
expressions, and variations or negatives of these words and include, but are
not limited to, statements regarding the advantages and efficacy of CMA over
standard karyotyping.These forward-looking statements are not guarantees of
future results and are subject to risks, uncertainties and assumptions that
could cause our actual results to differ materially and adversely from those
expressed in any forward-looking statement.The risks and uncertainties
referred to above include, but are not limited to:market acceptance of CMA as
a preferred method over karyotyping; the rate of transition to CMA from
karyotyping; our ability to successfully expand the base of our customers and
strategic partners, add to the menu of our diagnostic tests in both of our
primary markets, develop and introduce new tests and related reports, optimize
the reimbursements received for our testing services, and increase operating
margins by improving overall productivity and expanding sales volumes; our
ability to successfully accelerate sales, allow access to samples earlier in
the testing continuum, steadily increase the size of our customer rosters in
both developmental medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets; changes in
demand for our future products; legislative, regulatory and competitive
developments; general economic conditions; and various other factors.Further
information on potential factors that could affect our financial results is
included in our Annual Report on Form 10-K, Quarterly Reports of Form 10-Q,
and in other filings with the Securities and Exchange Commission.We undertake
no obligation to revise or update publicly any forward-looking statements for
any reason, except as required by law.

CONTACT: Company Contact:
         R. Judd Jessup
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com

CombiMatrix Corporation